Women offered jabs in HIV prevention trial
A six-monthly injection to reduce the risk of HIV transmission is being offered to sexually active women in parts of England as part of a new clinical study.
The study will be carried out in France and the UK, with centres in Birmingham, Manchester, London and Brighton.
The trial will offer participants a new, twice-yearly injectable PrEP (pre-exposure prophylaxis) medicine called Lenacapivir.
PrEP is currently offered on the NHS as a daily tablet which, if taken correctly, significantly reduces the risk of HIV in people likely to be exposed to the virus.
Dr Steve Taylor, a principal investigator for the Purpose 5 trial and Clinical Service Lead for the Birmingham Heartlands HIV service, said: "These injectable PrEP technologies have the potential to transform HIV prevention efforts in the UK and the wider world".
He said that in Africa, the Purpose 1 Trial was 100% effective with none of the 2,134 women given Lenacapavir becoming HIV positive.
Dr Taylor added: "Its aim is to determine whether the injections provide additional benefit as an HIV prevention strategy, and would be an attractive and acceptable option for women."
Women are being invited to take part as they are far less likely to take PrEP tablets to reduce their HIV risk.
Government figures found that 75% of men who have sex with men, who were identified as having a need for PrEP by NHS sexual health services in England, had started or continued to take it in 2023.
Fewer than 4% of all PrEP prescriptions in the UK are for women.
However, women who have sex with men now account for the highest proportion of new HIV diagnoses in England.
This group accounted for 46% of all new HIV transmissions through sex in England in 2023. Men who have sex with men accounted for 28%, and men who have sex with women 26%
Eligible participants in the study receive either a daily pill or the new six-monthly injection. The trial will last a minimum of two years and will require around four clinic visits a year.
Dan Hartland, chief executive of West Midlands HIV support charity Saving Lives, said: "Injectable, long-acting PrEP is a major advance in the field of HIV prevention, particularly for women. If we are to achieve the government target to eliminate new HIV transmissions by 2030, we need a combination approach of testing, treatment and preventative tools."
Dr Taylor asked women interested in participating in the Birmingham trial to email the team before the end of April.
Follow BBC Birmingham on BBC Sounds, Facebook, X and Instagram.
Annual jab for HIV protection passes trial hurdle
Preventative HIV drug highly effective, study says
Sussex launches new online HIV medication service
Birmingham Heartlands HIV Service
Saving Lives
Purpose Studies
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Robotic surgeries set to soar under NHS plans
The use of robotic surgery is set to soar in the NHS in England under plans to expedite care for patients. In 2023/24, some 70,000 robot-assisted surgeries were carried out in the NHS in England, but the number is expected to rise to around half a million over the next decade. NHS officials said that by 2035, it is expected that nine in 10 of all keyhole surgeries will be delivered with robot assistance – up from one in five at present. Health Secretary Wes Streeting, who had robot-assisted surgery when he had treatment for kidney cancer, said that innovative technologies will 'transform the NHS'. NHS England said that patients who have robotic assisted-surgery tend to recover quicker and are able to leave hospital sooner. Experts said that robotic surgery allows 'greater dexterity and are easier to manipulate' compared to traditional surgery. Surgeons control instruments using a console and a camera. In some othopaedic procedures, robots are programmed to perform elements of procedures. Officials said that the range of robotic-assisted procedures has widened in recent years and spans multiple areas of medicine. Speaking ahead of a speech at the NHS ConfedExpo conference in Manchester, NHS England boss Sir Jim Mackey said: 'The NHS has pledged to return to shorter elective waiting times by 2029 and we are using every tool at our disposal to ensure patients get the best possible treatment. 'Expanding the use of new and exciting tech such as robotic surgery will play a huge part in this. 'Not only does it speed up the number of procedures the NHS can do, but it also means better outcomes, a faster recovery and shorter hospital stays for patients.' Mr Streeting said: 'Innovative treatments and technologies that help fast track better outcomes for patients is how we transform our NHS and make it fit for the future. 'I know myself how important this is, when the NHS saved my life from kidney cancer with an operation led by a world-class surgeon being helped by a robot. 'Whether it's robotic surgery, our new health data research service to accelerate the development of new medicines, or announcing new artificial intelligence that detects skin cancer, our Plan for Change is driving forward new ways to help cut waiting lists and get patients treated on time again.' John McGrath, consultant surgeon at North Bristol NHS Trust and chair of the NHSE Steering Committee for Robotic Assisted Surgery, added: 'Robot-assisted surgery is a perfect example of innovation improving patients' care and transforming the way the NHS works – the number of procedures being carried is set to rapidly grow over the next 10 years according to our analysis. 'As keyhole surgery continues to develop and scale up in the NHS, it is likely that many of these procedures will be provided with degrees of robot assistance in the future. 'Faster recovery and shorter hospital stays are not only hugely important benefits for patients undergoing surgery, if used efficiently they can have a positive impact on the rest of the system by relieving pressure on services and therefore helping to reduce waiting times.'
Yahoo
7 hours ago
- Yahoo
MSPs vote to introduce scaled-back social care reforms
MSPs have unanimously passed legislation which will allow people in care homes to receive visits from a named loved one even in restricted measures. The Care Reform (Scotland) Bill will also introduce changes to social care procurement and a new right to breaks for unpaid carers. The legislation was backed by 116 votes to none. Plans to introduce a national care service, which were initially part of the bill, were dropped in January after unions withdrew support and a number of health boards and care organisations expressed concerns. One of the big changes planned under the new law is a legal right to breaks for unpaid carers. This mean councils will have a duty to decide whether a carer is able to take sufficient breaks from their caring role. If they are not, then the local authority will provide support to enable this, such as providing funding for short respite breaks. This policy, given Scotland has around 700,000 unpaid carers, will cost between £196m and £315m by 2035/36, according to the Bill's financial memorandum. However, it remains a fraction of the £13.9bn that unpaid care is currently saving Scotland every year. Improvements to the way information is shared in health and social care - to make it less likely that people will have to repeat their information - as well changes to procurement rules in the sector are also planned. Beefing up the powers that watchdogs can take against failing care providers is also part of the bill. The most high-profile part of the Care Reform (Scotland) Bill is Anne's Law, which allows people in care homes to receive visits from a named loved one even in restricted measures. It is named after Anne Duke, who died aged 63 in November 2021 after being cut off from her family while battling early-onset dementia during the Covid pandemic. The original proposal for a National Care Service, inspired by the NHS, was to take social care provision and staff away from local authorities into a new national agency. That was then dropped in favour of creating a national care board to supervise service delivery and improve consistency - but this failed to win over a growing number of critics. Council body Cosla and trade unions then withdrew their support for the project, while a number of health boards and care organisations also expressed concerns. The plan, which was also subject to a series of delays, was eventually scrapped in January after £30m was spent on the process. Social Care Minister Maree Todd said at the time she was "still committed to the ambitions of the National Care Service" but added the SNP no longer had the support it needed in parliament to pass its original plans into law. How the SNP's flagship social care reforms were scaled back Why was Scotland's National Care Service scrapped?
Yahoo
7 hours ago
- Yahoo
Groundbreaking cancer treatment which ‘destroys tumours with sound' to be rolled out on NHS
NHS patients will be the first in Europe to benefit from a pioneering new cancer treatment which uses ultrasound to destroy tumours. The technology, known as histotripsy, offers a non-invasive treatment capable of breaking down liver cancer tissue without surgery, radiation or chemotherapy, with minimal damage to the surrounding organs, according to the Department for Health and Social Care (DHSC). First approved by US regulators in October 2023, histotripsy uses pulsed sound waves to create 'bubble clouds' from gases present in the targeted tissue and tumour. When these bubbles pop, within microseconds, a shockwave is released which is capable of breaking up a mass and killing cancerous cells, while avoiding the harms of radiation and reducing the risks of bleeding, infection, and damage to surrounding non-targeted tissue. Treatment is delivered via a single session – potentially taking just 30 minutes – with limited or no pain, a quick recovery, and can be performed as a day case, according to the DHSC. The first NHS patients are set to be treated this summer at Addenbrooke's Hospital in Cambridge, where the technology – which uses a device called an Edison System, created by US firm HistoSonics – is being debuted after a donation from the Li Ka Shing Foundation. Cancer Research UK describes liver cancer as the 17th most common cancer in the UK and the 8th most frequent cause of cancer death. More than 8,000 people received a new diagnoses in 2022, with liver cancer incidence across the UK having surged by 42 per cent over the past decade, according to the British Liver Trust. So far, more than 1,500 patients worldwide have received treatment using histotripsy, mainly in the United States – following approval by the US Food and Drug Administration in late 2023. According to 12-month follow-up data from HistoSonics' previous clinical trials, which involved patients for whom other treatments had been either unsuccessful or unavailable, overall survival rates after one year were 73.3 per cent for primary liver cancer, and 48.6 per cent for those with secondary tumours. The paper, published in the Annals of Surgery journal in April, noted that both tumour control and survival rates were similar to those among other current treatments. The UK's new device is expected to be fully installed in Cambridge later this year, where it will be used initially to treat patients with primary and secondary liver tumours. Wider research on how this could potentially treat tumours in other organs – such as the pancreas and kidneys – is underway. The technology has been approved in the UK via the innovative devices access pathway, which aims to enable faster approvals of medical devices and treatments which evidence shows are safe, efficient and can fill unmet need. 'This is a strong example of smart, agile regulation in action,' said James Pound, of the Medicines and Healthcare products Regulatory Agency (MHRA). 'It's a major step forward for patients with liver cancer and shows how the UK can be a frontrunner in supporting responsible innovation that meets real clinical need.' While 'regulation is vital to protect patients', the government is 'slashing red tape, so game-changing new treatments reach the NHS front line quicker – transforming healthcare', said health secretary Wes Streeting. Hailing histotripsy as 'an exciting new technology that will make a huge difference to patients', Roland Sinker, chief executive of Cambridge University Hospitals, said: 'By offering this non-invasive, more targeted treatment we can care for more people as outpatients and free up time for surgeons to treat more complex cases. 'The faster recovery times mean patients will be able to return to their normal lives more quickly, which will also reduce pressure on hospital beds, helping us ensure that patients are able to receive the right treatment at the right time.' Fiona Carey, a kidney cancer patient who co-chairs Cambridge's patient advisory group, added: 'This is seriously good news. A new, non-invasive option to treat these cancers is very welcome indeed. 'For patients for whom ordinary surgery is no longer an option, this could make all the difference.'
